{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:34:10Z","timestamp":1792953250067,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13555-026-01925-5","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:43:44Z","timestamp":1789663424000},"page":"5529-5544","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-Level Cumulative Clinical Benefit of Brodalumab Over 52 Weeks: A Multicentre Real-World Study-IL PSO (Italian Landscape Psoriasis)"],"prefix":"10.1007","volume":"16","author":[{"given":"Luca","family":"Potestio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Corrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Maria","family":"Gaiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele Claudio","family":"Cozzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Maurelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nello","family":"Tommasino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Caccavale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Giovanni","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Sacchelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Michelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Valguarnera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Mozzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lussana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Mercadante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cangialosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia Veronica","family":"Di Brizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Scibetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Assorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Campoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Giuseppa","family":"Angileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Dattola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Trovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zerbinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Campanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lasagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bardazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Travaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Burlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-3988","authenticated-orcid":false,"given":"Diego","family":"Orsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"19","key":"1925_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"issue":"Suppl 2","key":"1925_CR2","doi-asserted-by":"publisher","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","volume":"64","author":"RG Langley","year":"2005","unstructured":"Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18\u201325. https:\/\/doi.org\/10.1136\/ard.2004.033217.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1925_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s13555-022-00690-5","volume":"12","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Gooderham M, Griffiths CEM, et al. Cumulative clinical benefits of biologics in the treatment of patients with moderate-to-severe psoriasis over 1 year: a network meta-analysis. Dermatol Ther (Heidelb). 2022;12(3):727\u201340. https:\/\/doi.org\/10.1007\/s13555-022-00690-5.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1925_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.det.2024.02.001","volume":"42","author":"AM Wride","year":"2024","unstructured":"Wride AM, Chen GF, Spaulding SL, Tkachenko E, Cohen JM. Biologics for psoriasis. Dermatol Clin. 2024;42(3):339\u201355. https:\/\/doi.org\/10.1016\/j.det.2024.02.001.","journal-title":"Dermatol Clin"},{"key":"1925_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01682","volume":"9","author":"NC Brembilla","year":"2018","unstructured":"Brembilla NC, Senra L, Boehncke WH. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018;9:1682. https:\/\/doi.org\/10.3389\/fimmu.2018.01682.","journal-title":"Front Immunol"},{"issue":"4","key":"1925_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/14712598.2019.1579794","volume":"19","author":"KM Beck","year":"2019","unstructured":"Beck KM, Koo J. Brodalumab for the treatment of plaque psoriasis: up-to-date. Expert Opin Biol Ther. 2019;19(4):287\u201392. https:\/\/doi.org\/10.1080\/14712598.2019.1579794.","journal-title":"Expert Opin Biol Ther"},{"issue":"14","key":"1925_CR7","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1503824.","journal-title":"N Engl J Med"},{"key":"1925_CR8","doi-asserted-by":"publisher","unstructured":"Orsini D, Fargnoli MC, Burlando M, et al. Brodalumab efficacy in psoriasis patients with inadequate response to IL-23 or IL-12\/23 inhibitors: multicenter italian retrospective analysis - IL PSO (Italian Landscape Psoriasis). Dermatol Pract Concept. 2025;15(4):e20256010. Published 2025 Oct 1. https:\/\/doi.org\/10.5826\/dpc.1504a6010.","DOI":"10.5826\/dpc.1504a6010"},{"issue":"4","key":"1925_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14041087","volume":"14","author":"D Orsini","year":"2025","unstructured":"Orsini D, Graceffa D, Burlando M, et al. Effectiveness of brodalumab for the treatment of moderate-to-severe psoriasis: a retrospective, real-world multicenter study with a focus on obese and multi-failure patients-IL PSO (Italian landscape psoriasis). J Clin Med. 2025;14(4):1087. https:\/\/doi.org\/10.3390\/jcm14041087.","journal-title":"J Clin Med"},{"issue":"1","key":"1925_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2452948","volume":"36","author":"D Orsini","year":"2025","unstructured":"Orsini D, Graceffa D, Burlando M, et al. Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study - IL PSO (Italian Landscape Psoriasis). J Dermatolog Treat. 2025;36(1):2452948. https:\/\/doi.org\/10.1080\/09546634.2025.2452948.","journal-title":"J Dermatolog Treat"},{"key":"1925_CR11","doi-asserted-by":"publisher","first-page":"adv00683","DOI":"10.2340\/actadv.v102.1993","volume":"102","author":"K Reich","year":"2022","unstructured":"Reich K, Tha\u00e7i D, Stingl G, et al. Safety of brodalumab in plaque psoriasis: integrated pooled data from five clinical trials. Acta Derm Venereol. 2022;102:adv00683. https:\/\/doi.org\/10.2340\/actadv.v102.1993.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1925_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jdv.12106","volume":"28","author":"PL Mattei","year":"2014","unstructured":"Mattei PL, Corey KC, Kimball AB. Psoriasis area severity index (PASI) and the dermatology life quality index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333\u20137. https:\/\/doi.org\/10.1111\/jdv.12106.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1925_CR13","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jaad.2019.12.038","volume":"82","author":"RB Warren","year":"2020","unstructured":"Warren RB, Gooderham M, Burge R, et al. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis. J Am Acad Dermatol. 2020;82(5):1138\u201349. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.038.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1925_CR14","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/ced\/llaf486","volume":"51","author":"D Orsini","year":"2026","unstructured":"Orsini D, Potestio L, Fargnoli MC, et al. Cumulative clinical benefits of biologic treatments in patients with moderate-to-severe psoriasis: an Italian real-life experience - IL PSO (Italian Landscape Psoriasis). Clin Exp Dermatol. 2026;51(3):418\u201326. https:\/\/doi.org\/10.1093\/ced\/llaf486.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"1925_CR15","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/jdv.16816","volume":"35","author":"RB Warren","year":"2021","unstructured":"Warren RB, Hansen JB, Reich K, Paul C, Puig L. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3. J Eur Acad Dermatol Venereol. 2021;35(2):450\u20137. https:\/\/doi.org\/10.1111\/jdv.16816.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1925_CR16","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1111\/jdv.17433","volume":"35","author":"K Reich","year":"2021","unstructured":"Reich K, Hansen JB, Puig L, Konstantinou MP, Warren RB. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3. J Eur Acad Dermatol Venereol. 2021;35(10):2034\u201344. https:\/\/doi.org\/10.1111\/jdv.17433.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1925_CR17","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1159\/000520290","volume":"238","author":"G Kokolakis","year":"2022","unstructured":"Kokolakis G, Vadstrup K, Hansen JB, Carrascosa JM. Brodalumab is associated with high rates of complete clearance and quality of life improvement: a subgroup analysis of patients with psoriasis and concomitant psoriatic arthritis. Dermatology (Basel). 2022;238(4):620\u20139. https:\/\/doi.org\/10.1159\/000520290.","journal-title":"Dermatology (Basel)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01925-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01925-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01925-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:00:52Z","timestamp":1792951252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01925-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1925"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01925-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"5 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Luca Mastorino served as a speaker and advisory board member for Leo Pharma, Almirall, Novartis, Eli Lilly, Accord, Pierre Fabre, UCB Pharma, and Johnson & Johnson. Francesca Maria Gaiani acted as a speaker or consultant for Novartis, AbbVie, Eli Lilly, Celgene, Leo Pharma, and Almirall. Martina Maurelli has received personal fees from Almirall, Johnson & Johnson Innovative Medicine, and Leo Pharma. Luigi Gargiulo has been a consultant and\/or speaker and has served as an advisory board member for AbbVie, Almirall, Amgen, Bristol Myers Squibb, Eli Lilly, Galderma, Johnson & Johnson, Incyte, LEO Pharma, Novartis, Pierre Fabre, Pfizer, Sanofi, and UCB Pharma. Carlo Giovanni Carrera declares consultancy\/advisory board disease-relevant honoraria from AbbVie, Almirall, Bristol Myers Squibb, Johnson & Johnson, Eli Lilly, Novartis, and UCB Pharma. Andrea Carugno has been a speaker and\/or consultant for Almirall, Amgen, AbbVie, Boehringer Ingelheim, Eli Lilly, Leo Pharma, Janssen-Cilag, Novartis, and UCB Pharma. Matteo Bianco has been a speaker for Bristol Myers Squibb. Annunziata Dattola has served as a speaker, consultant, or advisory board member for AbbVie, Almirall, Amgen, Eli Lilly, Leo Pharma, Janssen, Novartis, Boehringer Ingelheim, and UCB Pharma outside the submitted work. Maria Esposito has served as a speaker or consultant for AbbVie, Amgen, Almirall, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, UCB Pharma, and Sanofi-Regeneron. Nicola Zerbinati was Scientific Director of Matex Lab. Claudio Guarneri has served as an advisory board member and consultant, has received fees and speaker honoraria, or has participated in clinical trials for Pfizer, Janssen, Novartis, Merck Serono, Eli Lilly, Celgene, Leo Pharma, Leo Pharma Denmark, Almirall, Amgen, Sanofi-Aventis, Boehringer Ingelheim, Bristol Myers Squibb, and UCB Pharma. Francesco Loconsole served on advisory boards and\/or received honoraria for lectures from AbbVie, Janssen-Cilag, Novartis, Eli Lilly, and Sanofi. Anna Campanati has served as a speaker, consultant, or advisory board member for AbbVie, Almirall, Amgen, Eli Lilly, UCB Pharma, Pfizer, Leo Pharma, Novartis, Bristol Myers Squibb, Janssen, and Sanofi. Claudia Lasagni declares conflicts of interest with AbbVie, Novartis, Eli Lilly, and Almirall. Angelo Valerio Marzano declares consultancy\/advisory board disease-relevant honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Incyte, Johnson & Johnson, Leo Pharma, MSD, Novartis, Otsuka, Pfizer, Sanofi, Takeda, and UCB Pharma. Alessandra Narcisi has served on advisory boards and has received honoraria for lectures and research grants from Almirall, AbbVie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi Genzyme, Amgen, and Boehringer Ingelheim. Anna Balato has served as a speaker and\/or has received fees from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Incyte, Leo Pharma, Novartis, Pfizer, Sanofi, and UCB Pharma. Matteo Megna has acted as a speaker or consultant for AbbVie, Almirall, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, UCB Pharma, Novartis, and Leo Pharma. Giampiero Girolomoni has received personal fees from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Eli Lilly, Incyte, Johnson & Johnson Innovative Medicine, Leo Pharma, Merck Serono, Novartis, Pfizer, Samsung Bioepis, and Sanofi. Piergiorgio Malagoli has been a speaker for AbbVie, Eli Lilly, Novartis, Janssen-Cilag, Celgene, Leo Pharma, and Almirall. Simone Ribero has received research grants, travel support, and\/or consultancy fees from AbbVie, Almirall, Leo Pharma, Johnson & Johnson, L\u2019Or\u00e9al, Sanofi, Sandoz, UCB Pharma, Eli Lilly, Novartis, Bristol Myers Squibb, and Incyte. Diego Orsini has been a speaker and\/or consultant for AbbVie, Leo Pharma, UCB Pharma, Bristol Myers Squibb, and Boehringer Ingelheim. Anna Campanati and Diego Orsini are Editorial Board members of\n                      Dermatology and Therapy\n                      . Anna Campanati and Diego Orsini were not involved in the selection of peer reviewers for the manuscript or in any subsequent editorial decisions. Luca Potestio, Salvatore Corrao, Emanuele Claudio Cozzani, Nello Tommasino, Stefano Caccavale, Lidia Sacchelli, Caterina Longo, Sara Marchetti, Alessandra Michelucci, Dario Valguarnera, Simone Mozzato, Francesca Lussana, Lorenzo Mercadante, Luca Cangialosi, Francesco Messina, Eugenia Veronica Di Brizzi, Salvatore Scibetta, Chiara Assorgi, Marco Campoli, Rosa Giuseppa Angileri, Emanuele Trovato, Valentina Dini, Federico Bardazzi, Massimo Travaglini, and Martina Burlando declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Territorial Ethics Committee of the Calabria Region (Comitato Etico Territoriale Regione Calabria) for the LANDSCAPE study amendment (Protocol No. 164\/2026), which was approved on June 22, 2026. The study was conducted in accordance with the principles of the Declaration of Helsinki. All participants had provided written informed consent for the use of their anonymized clinical data.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}